BDX Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 5.86% compared to Becton Dickinson &'s net margin of 12.41%. Becton Dickinson &'s return on equity of 6.75% beat Boston Scientific's return on equity of 8.96%.

Becton Dickinson & has a consensus price target of $276.77, signalling upside risk potential of 23.66%. On the other hand Boston Scientific has an analysts' consensus of $115.62 which suggests that it could grow by 19.91%. Given that Becton Dickinson & has higher upside potential than Boston Scientific, analysts believe Becton Dickinson & is more attractive than Boston Scientific.

Becton Dickinson & has a beta of 0.355, which suggesting that the stock is 64.526% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.845%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 1.78%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Becton Dickinson &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.2B, which are larger than Boston Scientific quarterly revenues of $4.6B. Becton Dickinson &'s net income of $303M is lower than Boston Scientific's net income of $566M. Notably, Becton Dickinson &'s price-to-earnings ratio is 37.18x while Boston Scientific's PE ratio is 77.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 3.15x versus 8.56x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 5.86% compared to Becton Dickinson &'s net margin of -58.2%. Becton Dickinson &'s return on equity of 6.75% beat Masimo's return on equity of -23.05%.

Becton Dickinson & has a consensus price target of $276.77, signalling upside risk potential of 23.66%. On the other hand Masimo has an analysts' consensus of $193.76 which suggests that it could grow by 15.56%. Given that Becton Dickinson & has higher upside potential than Masimo, analysts believe Becton Dickinson & is more attractive than Masimo.

Becton Dickinson & has a beta of 0.355, which suggesting that the stock is 64.526% less volatile than S&P 500. In comparison Masimo has a beta of 1.035, suggesting its more volatile than the S&P 500 by 3.537%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 1.78%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend. Becton Dickinson &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.2B, which are larger than Masimo quarterly revenues of $600.7M. Becton Dickinson &'s net income of $303M is higher than Masimo's net income of -$349.6M. Notably, Becton Dickinson &'s price-to-earnings ratio is 37.18x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 3.15x versus 4.33x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems has a net margin of 5.86% compared to Becton Dickinson &'s net margin of 7.87%. Becton Dickinson &'s return on equity of 6.75% beat Merit Medical Systems's return on equity of 9.36%.

Becton Dickinson & has a consensus price target of $276.77, signalling upside risk potential of 23.66%. On the other hand Merit Medical Systems has an analysts' consensus of $118.20 which suggests that it could grow by 20.16%. Given that Becton Dickinson & has higher upside potential than Merit Medical Systems, analysts believe Becton Dickinson & is more attractive than Merit Medical Systems.

Becton Dickinson & has a beta of 0.355, which suggesting that the stock is 64.526% less volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.607%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 1.78%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend. Becton Dickinson &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.2B, which are larger than Merit Medical Systems quarterly revenues of $355.2M. Becton Dickinson &'s net income of $303M is higher than Merit Medical Systems's net income of $27.9M. Notably, Becton Dickinson &'s price-to-earnings ratio is 37.18x while Merit Medical Systems's PE ratio is 48.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 3.15x versus 4.31x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 5.86% compared to Becton Dickinson &'s net margin of 26.88%. Becton Dickinson &'s return on equity of 6.75% beat ResMed's return on equity of 25.56%.

Becton Dickinson & has a consensus price target of $276.77, signalling upside risk potential of 23.66%. On the other hand ResMed has an analysts' consensus of $269.38 which suggests that it could grow by 22.32%. Given that Becton Dickinson & has higher upside potential than ResMed, analysts believe Becton Dickinson & is more attractive than ResMed.

Becton Dickinson & has a beta of 0.355, which suggesting that the stock is 64.526% less volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 1.78%. ResMed offers a yield of 0.94% to investors and pays a quarterly dividend of $0.53 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.2B, which are larger than ResMed quarterly revenues of $1.3B. Becton Dickinson &'s net income of $303M is lower than ResMed's net income of $344.6M. Notably, Becton Dickinson &'s price-to-earnings ratio is 37.18x while ResMed's PE ratio is 26.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 3.15x versus 6.59x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.